Review



anti ubc13  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti ubc13
    Anti Ubc13, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ubc13/product/Cell Signaling Technology Inc
    Average 94 stars, based on 17 article reviews
    anti ubc13 - by Bioz Stars, 2026-06
    94/100 stars

    Images



    Similar Products

    e2 ag0292 proteins  (Proteintech)
    85
    Proteintech e2 ag0292 proteins
    E2 Ag0292 Proteins, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e2 ag0292 proteins/product/Proteintech
    Average 85 stars, based on 1 article reviews
    e2 ag0292 proteins - by Bioz Stars, 2026-06
    85/100 stars
    		  Buy from Supplier
    recombinant human ube2n protein ag0292  (Proteintech)
    85
    Proteintech recombinant human ube2n protein ag0292
    Recombinant Human Ube2n Protein Ag0292, supplied by Proteintech, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human ube2n protein ag0292/product/Proteintech
    Average 85 stars, based on 1 article reviews
    recombinant human ube2n protein ag0292 - by Bioz Stars, 2026-06
    85/100 stars
    		  Buy from Supplier
    ubc13 ube2n  (Proteintech)
    93
    Proteintech ubc13 ube2n
    Ubc13 Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ubc13 ube2n/product/Proteintech
    Average 93 stars, based on 1 article reviews
    ubc13 ube2n - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    ube2n  (Akizuki Denshi Tsusho Co Ltd)
    86
    Akizuki Denshi Tsusho Co Ltd ube2n
    Ube2n, supplied by Akizuki Denshi Tsusho Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ube2n/product/Akizuki Denshi Tsusho Co Ltd
    Average 86 stars, based on 1 article reviews
    ube2n - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    ube2n  (Proteintech)
    93
    Proteintech ube2n
    Ube2n, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ube2n/product/Proteintech
    Average 93 stars, based on 1 article reviews
    ube2n - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    ube2n  (Proteostasis Therapeutics)
    86
    Proteostasis Therapeutics ube2n
    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
    Ube2n, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ube2n/product/Proteostasis Therapeutics
    Average 86 stars, based on 1 article reviews
    ube2n - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    anti ubc13  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti ubc13
    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
    Anti Ubc13, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ubc13/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti ubc13 - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    4919s  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc 4919s
    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
    4919s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/4919s/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    4919s - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    anti ube2n antibody  (Proteintech)
    93
    Proteintech anti ube2n antibody
    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
    Anti Ube2n Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ube2n antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti ube2n antibody - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    ubiquitin-conjugating enzyme ube2n  (Proteostasis Therapeutics)
    90
    Proteostasis Therapeutics ubiquitin-conjugating enzyme ube2n
    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, <t>UBE2N),</t> rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.
    Ubiquitin Conjugating Enzyme Ube2n, supplied by Proteostasis Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ubiquitin-conjugating enzyme ube2n/product/Proteostasis Therapeutics
    Average 90 stars, based on 1 article reviews
    ubiquitin-conjugating enzyme ube2n - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, UBE2N), rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.

    Journal: Frontiers in Oncology

    Article Title: Rewiring tumor visibility: The immunopeptidome as a dynamic interface between antigen processing, microenvironmental stress, and immune recognition

    doi: 10.3389/fonc.2025.1691719

    Figure Lengend Snippet: Context-dependent dual roles of the immunoproteasome in cancer. The immunoproteasome (IP) exerts divergent functions depending on tumor type and microenvironmental context. On the pro-tumor side (red), IP activity sustains chronic inflammation, promotes IL-17/LMP7-driven prostate cancer progression, maintains AML stemness (PSMB10, UBE2N), rewires epigenetic and metabolic programs (DNMT1/3B loss, MCL-1 survival), and supports immune evasion via the USP24–STAT3–PD1 axis. Conversely, in immunogenic contexts (green), IP enhances tumor suppression by broadening the immunopeptidome and unmasking neoantigens, promoting CD8 + T-cell responses, with PSMB9 acting as a tumor suppressor in melanoma, glutamate flux inhibition boosting antigenicity in CRC, and dual MCL-1/MEK inhibition restoring therapy sensitivity in TNBC/IBC. High IP expression aligns with favorable prognosis in melanoma, bladder cancer, and TNBC. Notably, IP is dispensable for leukemia infected-cell vaccine efficacy (exception). Collectively, these findings position the IP as a context-dependent regulator, balancing between tumor-promoting inflammation and antigen-driven immune surveillance.

    Article Snippet: AML – UBE2N and proteostasis , UBE2N stabilizes proteins via K63 ubiquitination; its inhibition triggers K48-linked degradation through immunoproteasome, suppressing AML. , UBE2N is a vulnerability in immunoproteasome-positive AML; inhibition may serve as therapeutic strategy. , ( ) .

    Techniques: Activity Assay, Immunopeptidomics, Inhibition, Expressing, Infection